Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib. (10th April 2017)

• Record Type: Journal Article
• Authors: Jones, Jeffrey A.; Hillmen, Peter; Coutre, Steven; Tam, Constantine; Furman, Richard R.; Barr, Paul M.; Schuster, Stephen J.; Kipps, Thomas J.; Flinn, Ian W.; Jaeger, Ulrich; Burger, Jan A.; Cheng, Mei; Ninomoto, Joi; James, Danelle F.; Byrd, John C.; O'Brien, Susan M.
• Is Part Of: British journal of haematology. Volume 178:Number 2(2017)
• Page Start: 286
• Page End: 291
• Publication Date: 2017-04-10
• Subjects: anticoagulation -- bleeding -- chronic lymphocytic leukaemia -- haemorrhage -- ibrutinib; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.14660
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single‐agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib‐treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.